Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities:
Net loss	$ (162,155)	$ (166,037)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	32,466	33,963
Depreciation and amortization	2,098	2,227
Amortization of debt discount		785
Amortization of debt issuance costs	152	69
(Accretion of discount) amortization of premium on short-term investments	(162)	223
Impairment of property and equipment	130	354
Loss on disposal of property and equipment	74
Change in operating assets and liabilities:
Accounts receivable	(6,689)	(1,236)
Inventory	(3,857)	403
Prepaid expenses and other assets	5,726	(5,694)
Accounts payable	2,744	5,360
Accrued clinical and manufacturing liabilities	13,582	(32,811)
Accrued payroll and employee liabilities	(555)	2,409
Other accrued and other non-current liabilities	7,068	1,889
Net cash used in operating activities	(109,378)	(158,096)
Investing activities:
Purchases of short-term investments	(127,115)	(91,321)
Maturities and sales of short-term investments	122,957	150,940
Purchases of property and equipment	(1,411)	(2,632)
Proceeds from the sale of property and equipment	224
Net cash (used in) provided by investing activities	(5,345)	56,987
Financing activities:
Net proceeds from convertible note financing		148,963
Net proceeds from private placement	75,163
Net proceeds from issuance of common stock under equity incentive plan	(1,315)	5,049
Proceeds from purchases under the employee stock purchase plan	772	1,529
Net cash provided by financing activities	74,620	155,541
Net (decrease) increase in cash and cash equivalents	(40,103)	54,432
Cash and cash equivalents at beginning of year	90,541	105,138
Cash and cash equivalents at end of period	50,438	$ 159,570
Supplemental disclosure of cash flow information:
Interest paid	$ 1,125